Komori
T

TAKARA BIO INC.

4974Materials and ChemicalsMid cap
1,144JPY+0.2%
★ Watch (sign-up required)
Price history
¥1,144Latest-58.1%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

A summary lands here once the filings have been read.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 16
PER
107.81How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1.36How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
-9.5%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥138bnShare price × number of shares. The value of the entire company.
Equity ratio
77.4%The proportion of assets funded by money that does not have to be repaid.
Operating margin
-17.1%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
-22.2%The average annual growth in sales over the past three years.
What to watch next
Construction through completion of Building 3 at the Gene and Cell Processing Center, providing a concrete expansion of capacity
Construction scheduled to begin in fiscal 2024 and be completed in fiscal 2027, based on the current planImpact HighLikelihood Medium
Completion and start of operations of dual-use manufacturing facilities for vaccine-related and CDMO businesses
Scheduled for completion in June 2027, based on the current planImpact HighLikelihood Medium
Expansion of CDMO applications in compliance with GCTP and GMP requirements, together with disclosure of progress in building the project pipeline
Impact MediumLikelihood Medium
Progress in integrating Curio Bioscience’s spatial analysis technologies following the acquisition, including the rollout of contract services, instruments and reagents
From 2026 onward, with further disclosure awaited as integration gets underwayImpact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 70.9%
Listed holders 70.9%Everyone else 29.1%
TAKARA HOLDINGS INC.60.91%
The Master Trust Bank of Japan, Ltd. (Trust Account)5.28%
Custody Bank of Japan, Ltd. (Trust Account).1.76%
JP MORGAN CHASE BANK 385781 (Standing proxy: Mizuho Bank)0.56%
STATE STREET BANK WEST CLIENT-TREATY 505234 (standing proxy: Mizuho Bank)0.54%
STATE STREET BANK AND TRUST COMPANY 505001 (standing proxy: Mizuho Bank)0.45%
The Bank of Kyoto, Ltd.0.42%
タカラバイオ従業員持株会0.36%
2 other listed holders0.65%
Who owns it
HolderOwnership (%)
TAKARA HOLDINGS INC.60.91
The Master Trust Bank of Japan, Ltd. (Trust Account)5.28
Custody Bank of Japan, Ltd. (Trust Account).1.76
JP MORGAN CHASE BANK 385781 (Standing proxy: Mizuho Bank)0.56
STATE STREET BANK WEST CLIENT-TREATY 505234 (standing proxy: Mizuho Bank)0.54
STATE STREET BANK AND TRUST COMPANY 505001 (standing proxy: Mizuho Bank)0.45
The Bank of Kyoto, Ltd.0.42
タカラバイオ従業員持株会0.36
2 other listed holders0.65
This company's documents
Filings
Timely disclosures
Threads